Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in the absence of CD28 costimulation GRC ...

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast CancerCasitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase ...

I-DXd targets B7-H3, a protein overexpressed on the surface of a wide variety of cancer cells that binds to the CD28 family of receptors, which includes PD-1, targeted by MSD's widely used ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...

It switched its focus to autoimmune and inflammatory diseases, led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results ...

Sam and Danni start Friday on Radio 1.

New additions are in bold.

Division of Neuro-Oncology, Department of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.

Experimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.